title: Significance of matrix metalloproteinase-9 in cardiac dysfunction during the very acute phase after myocardial infarction in hamsters.
abstract: Matrix metalloproteinase-9 activity is dramatically increased during the acute phase after myocardial infarction. However, the relationship between matrix metalloproteinase-9 activity and cardiac dysfunction is unclear. In 1-day post-myocardial infarction hamsters, matrix metalloproteinase-9 activity was significantly increased, while matrix metalloproteinase-2 activity was not increased. A selective matrix metalloproteinase inhibitor, [2S,4S]-N-Hydroxy-5-ethoxymethyloxy-2-methyl-4-[4-phenoxybenzoyl] aminopentanamide (ONO-4817), significantly suppressed matrix metalloproteinase-9 activity 1 day after myocardial infarction. ONO-4817 also significantly prevented the development of cardiac dysfunction and left-ventricular dilatation. Matrix metalloproteinase-9 might play a crucial role in cardiac dysfunction and left-ventricular dilatation during the very acute phase after myocardial infarction.
authors.affiliation: Department of Pharmacology, Osaka Medical College, Takatsuki City 589-8686, Japan. pha010@art.osaka-med.ac.jp
authors.forename: Shinji
authors.initials: S
authors.lastname: Takai
authors.forename: Denan
authors.initials: D
authors.lastname: Jin
authors.forename: Sachiko
authors.initials: S
authors.lastname: Inagaki
authors.forename: Daisuke
authors.initials: D
authors.lastname: Yamamoto
authors.forename: Kazuhiko
authors.initials: K
authors.lastname: Tanaka
authors.forename: Mizuo
authors.initials: M
authors.lastname: Miyazaki
mesh_terms: D000818:Animals; D006224:Cricetinae; D017379:Hypertrophy, Left Ventricular / Q000000981:diagnostic imaging / Q000517:prevention & control; D008297:Male; D020778:Matrix Metalloproteinase 2 / Q000378:metabolism; D020780:Matrix Metalloproteinase 9 / Q000378:metabolism; D061965:Matrix Metalloproteinase Inhibitors; D008647:Mesocricetus; D009203:Myocardial Infarction / Q000000981:diagnostic imaging / Q000201:enzymology* / Q000503:physiopathology; D010647:Phenyl Ethers / Q000494:pharmacology; D013997:Time Factors; D014463:Ultrasonography
chemical_list: D061965:Matrix Metalloproteinase Inhibitors; C414368:N-hydroxy-5-ethoxymethyloxy-2-methyl-4-(4-phenoxybenzoyl)aminopentanamide; D010647:Phenyl Ethers; D020778:Matrix Metalloproteinase 2; D020780:Matrix Metalloproteinase 9